| 76.01 0 (0%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 88.81 | 1-year : | 103.73 |
| Resists | First : | 76.04 | Second : | 88.81 |
| Pivot price | 75.56  |
|||
| Supports | First : | 75.39 | Second : | 75 |
| MAs | MA(5) : | 75.77 |
MA(20) : | 75.49 |
| MA(100) : | 75.03 |
MA(250) : | 68.89 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 92.4 |
D(3) : | 85.6 |
| RSI | RSI(14): 68.7 | |||
| 52-week | High : | 76.04 | Low : | 51.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HOLX ] has closed below upper band by 5.6%. Bollinger Bands are 25.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 76.07 - 76.46 | 76.46 - 76.7 |
| Low: | 75.07 - 75.59 | 75.59 - 75.93 |
| Close: | 75.27 - 76.05 | 76.05 - 76.55 |
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Fri, 12 Jun 2026
First Trust Merger Arbitrage Fund's Hologic Inc(HOLX) Holding History - GuruFocus
Wed, 08 Apr 2026
Hologic, Inc.(NasdaqGS: HOLX) dropped from S&P Composite 1500 - marketscreener.com
Tue, 07 Apr 2026
TPG, Blackstone Take Hologic Private in $18.3B Deal; José Almeida Named CEO - Dallas Innovates
Tue, 07 Apr 2026
Blackstone and TPG Complete Acquisition of Hologic - TPG Inc.
Mon, 06 Apr 2026
Hologic closing $18B merger deal as CEO announces retirement - Radiology Business
Tue, 31 Mar 2026
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 223 (M) |
| Shares Float | 221 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 96.5 (%) |
| Shares Short | 7,100 (K) |
| Shares Short P.Month | 4,830 (K) |
| EPS | 2.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 23.51 |
| Profit Margin | 13.1 % |
| Operating Margin | 22.9 % |
| Return on Assets (ttm) | 7.4 % |
| Return on Equity (ttm) | 10.8 % |
| Qtrly Rev. Growth | 2.5 % |
| Gross Profit (p.s.) | 11.15 |
| Sales Per Share | 18.5 |
| EBITDA (p.s.) | 6.04 |
| Qtrly Earnings Growth | -9.2 % |
| Operating Cash Flow | 1,100 (M) |
| Levered Free Cash Flow | 849 (M) |
| PE Ratio | 31.53 |
| PEG Ratio | 0 |
| Price to Book value | 3.23 |
| Price to Sales | 4.1 |
| Price to Cash Flow | 15.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|